BRPI0509710A - formulação de liberação controlada para administração oral de inibidor de hmg-coa redutase e método para preparação da mesma - Google Patents
formulação de liberação controlada para administração oral de inibidor de hmg-coa redutase e método para preparação da mesmaInfo
- Publication number
- BRPI0509710A BRPI0509710A BRPI0509710-0A BRPI0509710A BRPI0509710A BR PI0509710 A BRPI0509710 A BR PI0509710A BR PI0509710 A BRPI0509710 A BR PI0509710A BR PI0509710 A BRPI0509710 A BR PI0509710A
- Authority
- BR
- Brazil
- Prior art keywords
- hmg
- controlled release
- release formulation
- oral administration
- coa reductase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
FORMULAçAO DE LIEERAçAO CONTROLADA PARA ADMINISTRAçAO ORAL DE INIBIDOR DE HMG-COA REDUTASE E METODO PARA PREPARAçAO DA MESMA. A formulação de liberação controlada para administração oral de um inibidor de HMG-COA redutase da presente invenção pode ser facilmente e economicamente preparada sendo capaz de manter um nível de fárrnaco constante no sangue por liberação lenta do inibidor de HMG-COA redutase a uma velocidade uniforme pro 24 horas. Conseqüentemente, a formulação de liberação controlada da presente invenção, pode ser eficazmente empregada para baixar os níveis de colesterol e triglicérides do sangue.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040024734A KR100598326B1 (ko) | 2004-04-10 | 2004-04-10 | HMG-CoA 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법 |
PCT/KR2005/001021 WO2005097194A1 (en) | 2004-04-10 | 2005-04-08 | Sustained release formulation for oral administration of hmg-coa reductase inhibitor and method for the preparation thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
BRPI0509710A true BRPI0509710A (pt) | 2007-09-18 |
BRPI0509710A8 BRPI0509710A8 (pt) | 2016-06-07 |
Family
ID=35124845
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0509710A BRPI0509710A8 (pt) | 2004-04-10 | 2005-04-08 | Formulação de liberação controlada para administração oral de inibidor de hmg-coa redutase e método para preparação da mesma |
Country Status (15)
Country | Link |
---|---|
US (1) | US8475840B2 (pt) |
EP (1) | EP1744782A4 (pt) |
JP (1) | JP4740945B2 (pt) |
KR (1) | KR100598326B1 (pt) |
CN (1) | CN1946426B (pt) |
AU (1) | AU2005230362B2 (pt) |
BR (1) | BRPI0509710A8 (pt) |
CA (1) | CA2562418C (pt) |
IL (1) | IL178475A (pt) |
MX (1) | MXPA06011517A (pt) |
NO (1) | NO20065152L (pt) |
NZ (1) | NZ550326A (pt) |
RU (1) | RU2336903C2 (pt) |
WO (1) | WO2005097194A1 (pt) |
ZA (1) | ZA200609291B (pt) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1968558B1 (en) * | 2005-12-27 | 2016-12-28 | MonoSol Rx, LLC | Ph modulated films for delivery of actives |
CN101426478A (zh) * | 2006-02-24 | 2009-05-06 | 特瓦制药工业有限公司 | 氟伐他汀钠药物组合物 |
KR100791256B1 (ko) * | 2006-03-17 | 2008-01-03 | 주식회사 대웅제약 | 약학적으로 유용하고 안정한 아토바스타틴 고체분산체 및이를 포함하는 조성물 |
GB0613925D0 (en) * | 2006-07-13 | 2006-08-23 | Unilever Plc | Improvements relating to nanodispersions |
EP1911441A3 (en) * | 2006-10-11 | 2008-08-06 | Lupin Limited | Controlled release color stable pharmaceutical dosage form of HMG-COA reductase inhibitors, free of alkalizing or buffering agents |
IS8612A (is) * | 2007-02-19 | 2008-08-20 | Actavis Group Ptc Ehf. | Stöðugar statínlyfjasamsetningar |
TR200800634A2 (tr) * | 2008-01-30 | 2009-02-23 | Takka Sevgi̇ | Uzatılmış salım sağlayan fluvastatin tablet. |
US8282977B2 (en) | 2008-03-20 | 2012-10-09 | Virun, Inc. | Compositions containing non-polar compounds |
ES2664729T3 (es) * | 2009-12-30 | 2018-04-23 | Bcworld Pharm. Co. Ltd. | Composición farmacéutica que comprende metformina y rosuvastatina |
KR101622441B1 (ko) * | 2010-03-23 | 2016-05-18 | 버런, 아이엔씨. | 자당 지방산 에스테르를 포함하는 나노에멀전 |
US9351517B2 (en) | 2013-03-15 | 2016-05-31 | Virun, Inc. | Formulations of water-soluble derivatives of vitamin E and compositions containing same |
US9861611B2 (en) | 2014-09-18 | 2018-01-09 | Virun, Inc. | Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same |
WO2022129003A1 (en) * | 2020-12-15 | 2022-06-23 | Dsm Ip Assets B.V. | Multiparticulate solid oral dosage form comprising statin and vitamin e |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5612114B2 (pt) | 1974-06-07 | 1981-03-18 | ||
US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
DK149080C (da) | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
SE8601624D0 (sv) * | 1986-04-11 | 1986-04-11 | Haessle Ab | New pharmaceutical preparations |
US5135757A (en) * | 1988-09-19 | 1992-08-04 | Edward Mendell Co., Inc. | Compressible sustained release solid dosage forms |
JPH04234812A (ja) | 1990-03-16 | 1992-08-24 | Yamanouchi Pharmaceut Co Ltd | 持続性製剤用顆粒 |
EP0465096A1 (en) | 1990-06-26 | 1992-01-08 | Merck & Co. Inc. | Plasma cholesterol level lowering composition |
US5543154A (en) * | 1991-12-27 | 1996-08-06 | Merck & Co., Inc. | Controlled release nifedipine delivery device |
US5433951A (en) * | 1993-10-13 | 1995-07-18 | Bristol-Myers Squibb Company | Sustained release formulation containing captopril and method |
US5582838A (en) * | 1994-12-22 | 1996-12-10 | Merck & Co., Inc. | Controlled release drug suspension delivery device |
SI9500173B (sl) | 1995-05-19 | 2002-02-28 | Lek, | Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo |
IE80467B1 (en) | 1995-07-03 | 1998-07-29 | Elan Corp Plc | Controlled release formulations for poorly soluble drugs |
US5916595A (en) | 1997-12-12 | 1999-06-29 | Andrx Pharmaceutials, Inc. | HMG co-reductase inhibitor |
US20040029962A1 (en) * | 1997-12-12 | 2004-02-12 | Chih-Ming Chen | HMG-COA reductase inhibitor extended release formulation |
UA73092C2 (uk) * | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
SI20109A (sl) | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
US6569461B1 (en) * | 1999-03-08 | 2003-05-27 | Merck & Co., Inc. | Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors |
US20020028240A1 (en) * | 2000-04-17 | 2002-03-07 | Toyohiro Sawada | Timed-release compression-coated solid composition for oral administration |
US20020044962A1 (en) | 2000-06-06 | 2002-04-18 | Cherukuri S. Rao | Encapsulation products for controlled or extended release |
JP2001233766A (ja) | 2000-11-15 | 2001-08-28 | Ohara Yakuhin Kogyo Kk | プラバスタチンナトリウムの錠剤 |
US6524615B2 (en) * | 2001-02-21 | 2003-02-25 | Kos Pharmaceuticals, Incorporated | Controlled release pharmaceutical composition |
US20030091630A1 (en) * | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
AR040588A1 (es) * | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
KR100548925B1 (ko) * | 2002-10-23 | 2006-02-02 | 한미약품 주식회사 | 약물의 경구투여용 서방성 조성물 |
-
2004
- 2004-04-10 KR KR1020040024734A patent/KR100598326B1/ko active IP Right Grant
-
2005
- 2005-04-08 AU AU2005230362A patent/AU2005230362B2/en not_active Ceased
- 2005-04-08 US US10/599,729 patent/US8475840B2/en not_active Expired - Fee Related
- 2005-04-08 RU RU2006139748/15A patent/RU2336903C2/ru not_active IP Right Cessation
- 2005-04-08 JP JP2007507248A patent/JP4740945B2/ja not_active Expired - Fee Related
- 2005-04-08 EP EP05733408A patent/EP1744782A4/en not_active Withdrawn
- 2005-04-08 NZ NZ550326A patent/NZ550326A/en not_active IP Right Cessation
- 2005-04-08 BR BRPI0509710A patent/BRPI0509710A8/pt not_active IP Right Cessation
- 2005-04-08 MX MXPA06011517A patent/MXPA06011517A/es active IP Right Grant
- 2005-04-08 CN CN2005800122135A patent/CN1946426B/zh active Active
- 2005-04-08 CA CA002562418A patent/CA2562418C/en not_active Expired - Fee Related
- 2005-04-08 WO PCT/KR2005/001021 patent/WO2005097194A1/en active Application Filing
-
2006
- 2006-10-05 IL IL178475A patent/IL178475A/en not_active IP Right Cessation
- 2006-11-08 ZA ZA200609291A patent/ZA200609291B/en unknown
- 2006-11-09 NO NO20065152A patent/NO20065152L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR100598326B1 (ko) | 2006-07-10 |
EP1744782A4 (en) | 2011-02-16 |
NO20065152L (no) | 2006-12-07 |
RU2006139748A (ru) | 2008-05-20 |
IL178475A (en) | 2014-03-31 |
NZ550326A (en) | 2010-08-27 |
AU2005230362A1 (en) | 2005-10-20 |
MXPA06011517A (es) | 2007-01-16 |
US20070196480A1 (en) | 2007-08-23 |
CA2562418A1 (en) | 2005-10-20 |
BRPI0509710A8 (pt) | 2016-06-07 |
US8475840B2 (en) | 2013-07-02 |
RU2336903C2 (ru) | 2008-10-27 |
IL178475A0 (en) | 2007-02-11 |
JP2007532532A (ja) | 2007-11-15 |
CN1946426A (zh) | 2007-04-11 |
EP1744782A1 (en) | 2007-01-24 |
KR20050099583A (ko) | 2005-10-13 |
WO2005097194A1 (en) | 2005-10-20 |
AU2005230362B2 (en) | 2007-10-18 |
ZA200609291B (en) | 2008-05-28 |
JP4740945B2 (ja) | 2011-08-03 |
CA2562418C (en) | 2009-02-10 |
CN1946426B (zh) | 2010-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0509710A (pt) | formulação de liberação controlada para administração oral de inibidor de hmg-coa redutase e método para preparação da mesma | |
EP2943222B1 (en) | Solid solution compositions and use in severe pain | |
US10695432B2 (en) | Solid solution compositions and use in severe pain | |
BRPI0519684A2 (pt) | formulaÇço complexa de inibidor de reductase 3 hidràxi-metil glutaril coa e agente anti-hipertensço, e processo para preparaÇço da mesma | |
BRPI0516830A (pt) | composições de droga de liberação sustentada convenientemente implantáveis | |
AR073123A1 (es) | Composicion farmaceutica que comprende un taxano sustancialmente amorfo para utilizarse en el tratamiento de la enfermedad neoplasica | |
US10695431B2 (en) | Solid solution compositions and use in cardiovascular disease | |
WO2008079404A3 (en) | Pharmaceutical compositions for treatment of parkinson's disease and related disorders | |
BRPI0507198A (pt) | derivados de bisariluréia | |
AR075204A1 (es) | Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2 | |
NO20084049L (no) | Forbindelser med forsterket ampa receptor og anvendelse derav i medisin | |
US20170043016A1 (en) | Solid Solution Compositions and Use in Severe Pain | |
AR066214A1 (es) | Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas. usos y composiciones farmaceuticas | |
EA201071035A1 (ru) | Фармацевтические композиции модифицированного высвобождения, содержащие микофенолат, и способ их получения | |
EA200870368A1 (ru) | Антибиотические композиции с модифицированным высвобождением и способ их получения | |
UY29258A1 (es) | Ácidos hidroxibifenilcarboxílicos y derivados, procedimientos para prepararlos y su uso | |
BR112012031288A2 (pt) | composições | |
BRPI0515991A (pt) | derivados de bisariluréia substituìda heterocìclica como inibidores de cinase | |
DK2319517T3 (da) | Anvendelse af prodrugs til okulær, intravenøs administration | |
AU2010212580A8 (en) | Stable pharmaceutical composition for atherosclerosis | |
WO2008088039A1 (ja) | ドネペジルを含有する安定化医薬組成物、その製造方法、及び安定化方法 | |
JOP20190058B1 (ar) | مشتقات كرومان، أيزوكرومان وداي هيدرو أيزو بنزوفوران كمُعدلات تفارغية سالبة mGluR2، تركيبات، واستخدامها | |
US11918654B2 (en) | Solid solution compositions and use in severe pain | |
NO20092763L (no) | Isosorbid mononitrat derivater for behandling av tarmlidelser | |
US20220096637A1 (en) | Solid Solution Compositions and Use in Cardiovascular Disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: HANMI HOLDINGS CO., LTD. (KR) Free format text: TRANSFERIDO DE: HANMI PHARM. CO., LTD. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: PAGAR RESTAURACAO. |
|
B08H | Application fees: decision cancelled [chapter 8.8 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 NA RPI 2260 DE 29/04/2014 |
|
B25D | Requested change of name of applicant approved |
Owner name: HANMI SCIENCE CO., LTD. (KR) |
|
B25G | Requested change of headquarter approved |
Owner name: HANMI SCIENCE CO., LTD. (KR) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2471 DE 15/05/2018. |